BiotechTube
Oregon Therapeutics

Oregon Therapeutics

Paris, France· Est.
oregon-therapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Oregon Therapeutics is a preclinical-stage biotech focused on oncology, leveraging an onco-metabolism platform to develop PDI inhibitors. Its lead candidate, XCE853, is positioned as a first- and best-in-class therapy, with initial priority indications in ovarian and advanced pancreatic cancer. The company, led by a small team of industry veterans, aims to enter clinical trials within two years, targeting a significant unmet need in hard-to-treat cancers.

Oncology

Technology Platform

Onco-Metabolism platform focused on inhibiting Protein Disulfide Isomerase (PDI) to exploit metabolic vulnerabilities in cancer cells.

Opportunities

A first-in-class PDI inhibitor could address high-unmet-need cancers like pancreatic and ovarian, representing a multi-billion dollar market.
The platform's potential applicability across multiple solid tumor types offers significant expansion and partnership opportunities.

Risk Factors

High scientific risk associated with a novel, unproven mechanism of action in humans.
Significant financial risk as a pre-revenue company requiring substantial capital to reach clinical trials.
Execution risk is concentrated on a single asset.

Competitive Landscape

The competitive landscape for PDI inhibitors in oncology appears relatively open, with no approved therapies. However, several academic institutions and potentially other biotechs are researching the target, and competition may emerge. The primary competition remains standard-of-care chemotherapies and targeted therapies for the indicated cancers.

More companies in Small Molecule Drugs →More companies in France →